Kazumi Shiosaki, Ph.D.

Kasumi Shiosaki, Ph.D. headshot

Kazumi Shiosaki, Ph.D.

President and CEO, TwentyeightSeven
Managing Director, MPM Capital
Co-founder and CEO, Mitobridge
Co-founder and start-up CEO, Epizyme

Kazumi Shiosaki's Bio

Kazumi Shiosaki, Ph.D., has served on the Sanford Burnham Prebys Board of Trustees since 2017.

Shiosaki is currently CEO of Twentyeight-Seven, a biotechnology company focused on modulating non-coding RNA biology to develop treatments for cancer and other diseases. Shiosaki co-founded the company with prominent Harvard University investigators.

She is also managing director of MPM Capital; co-founder, CEO and president of Mitobridge, Inc., a start-up developing mitochondrial drugs for the treatment of muscle and kidney diseases and co-founder and CEO of Epizyme. Previously, she has been an executive leader at Primera Diagnostics, Millenium Pharmaceuticals, Sideris Pharmaceuticals and Galnea Corp.

She has a Bachelor of Science degree in chemistry from Whitman College and a Doctor of Philosophy degree in synthetic chemistry from the University of California Berkeley. 

scientist at work